Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

CNS 2NET 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × gadoteridol × Clear all
NCT04373564 2026-01-22

ODYSSEY

Guerbet

Phase 4 Recruiting
2,076 enrolled
BreastEndocrineGastrointestinalGenitourinaryNET

Breast Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT04608812 2023-08-18

Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection

OncoSynergy, Inc.

Phase 1 Terminated
7 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma

NCT00522951 2017-08-28

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Bayer

Phase 3 Completed
165 enrolled 24 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡